Aldosterone, aldosterone receptor blockers and chronic kidney disease

Abstract

Chronic kidney disease (CKD) is a worldwide public health problem and an important risk factor for cardiovascular events, morbidity and mortality. The renin-angiotensin-aldosteron system (RAAS) drugs, angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers contribute to a better evaluation of patients with CKD. Despite good efficacy of mentioned drugs, progressive decline of kidney function was observed, suggesting a hypothesis that both aldosterone activity related mechanism and some RAAS independent mechanisms may result in progressive kidney failure. The author of the article described the role of aldosterone and aldosterone receptor blockers in patients with CKD.